Regeneron Pharmaceuticals, Inc. (ETR:RGO)

Market Cap	70.26B
Revenue (ttm)	12.14B
Net Income (ttm)	3.90B
Shares Out	n/a
EPS (ttm)	35.45
PE Ratio	18.01
Forward PE	16.65
Dividend	3.40 (0.49%)
Ex-Dividend Date	Nov 20, 2025

Volume	31
Average Volume	52
Open	696.00
Previous Close	700.60
Day's Range	688.20 - 702.60
52-Week Range	464.70 - 702.60
Beta	n/a
RSI	65.75
Earnings Date	Jan 30, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,106
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: RGO

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD